78 related articles for article (PubMed ID: 37188186)
1. Telangiectatic osteosarcoma: Outcome analyses and a diagnostic model for differentiation from aneurysmal bone cyst.
Yin JQ; Fu YW; Xie XB; Cheng XY; Yang XY; Liu WH; Tu J; Gao ZH; Shen JN
J Bone Oncol; 2018 Jun; 11():10-16. PubMed ID: 29892520
[TBL] [Abstract][Full Text] [Related]
2. Survival Analysis of 3 Different Age Groups and Prognostic Factors among 402 Patients with Skeletal High-Grade Osteosarcoma. Real World Data from a Single Tertiary Sarcoma Center.
Evenhuis RE; Acem I; Rueten-Budde AJ; Karis DSA; Fiocco M; Dorleijn DMJ; Speetjens FM; Anninga J; Gelderblom H; van de Sande MAJ
Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33513855
[TBL] [Abstract][Full Text] [Related]
3. NECPAL prognostic tool: a palliative medicine retrospective cohort study.
Turrillas P; Peñafiel J; Tebé C; Amblàs-Novellas J; Gómez-Batiste X
BMJ Support Palliat Care; 2021 Feb; ():. PubMed ID: 33593868
[TBL] [Abstract][Full Text] [Related]
4. Resource-appropriate selection of osteosarcoma treatment protocols in low- and middle-income countries.
Mailankody S; Kumar VS; Khan SA; Banavali SD; Bajpai J
Pediatr Blood Cancer; 2022 Mar; 69(3):e29540. PubMed ID: 34971016
[TBL] [Abstract][Full Text] [Related]
5. Analysis of chemotherapy dosage and dosage intensity and survival outcomes of high-grade osteosarcoma patients younger than 40 years.
Sun L; Li Y; Li H; Zhang J; Li B; Ye Z
Clin Ther; 2014 Apr; 36(4):567-78. PubMed ID: 24636527
[TBL] [Abstract][Full Text] [Related]
6. Formulation and validation of a baseline prognostic score for osteosarcoma treated uniformly with a non-high dose methotrexate-based protocol from a low middle income healthcare setting: a single centre analysis of 594 patients.
Ganguly S; Sasi A; Khan SA; Kumar VS; Kapoor L; Sharma MC; Mridha A; Barwad A; Thulkar S; Pushpam D; Bakhshi S
Front Oncol; 2023; 13():1148480. PubMed ID: 37188186
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a prognostic score at baseline diagnosis for Ewing sarcoma family of tumors: a retrospective single institution analysis of 860 patients.
Sasi A; Ganguly S; Biswas B; Pushpam D; Kumar A; Agarwala S; Khan SA; Kumar VS; Deo S; Sharma DN; Biswas A; Mridha A; Barwad A; Thulkar S; Bakhshi S
Am J Transl Res; 2022; 14(2):927-941. PubMed ID: 35273696
[TBL] [Abstract][Full Text] [Related]
8. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'.
Bajpai J; Chandrasekharan A; Talreja V; Simha V; Chandrakanth MV; Rekhi B; Khurana S; Khan A; Vora T; Ghosh J; Banavali SD; Gupta S
Eur J Cancer; 2017 Nov; 85():49-58. PubMed ID: 28888849
[TBL] [Abstract][Full Text] [Related]
9. Outcomes in Treatment-Naïve Patients With Metastatic Extremity Osteosarcoma Treated With OGS-12, a Novel Non-High-Dose Methotrexate-Based, Dose-Dense Combination Chemotherapy, in a Tertiary Care Cancer Center.
Bajpai J; Chandrasekharan A; Simha V; Talreja V; Karpe A; Pandey N; Singh A; Rekhi B; Vora T; Ghosh J; Banavali S; Gupta S
J Glob Oncol; 2018 Sep; 4():1-10. PubMed ID: 30241240
[TBL] [Abstract][Full Text] [Related]
10. Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single-center experience of 237 patients.
Nataraj V; Batra A; Rastogi S; Khan SA; Sharma MC; Vishnubhatla S; Bakhshi S
J Surg Oncol; 2015 Nov; 112(6):662-8. PubMed ID: 26381138
[TBL] [Abstract][Full Text] [Related]
11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
12. Odds of Stage IV Bone Cancer Diagnosis Based on Socioeconomic and Geographical Factors: A National Cancer Database (NCDB) Review.
McMahon KM; Eaton V; Srikanth KK; Tupper C; Merwin M; Morris M; Silberstein PT
Cureus; 2023 Feb; 15(2):e34819. PubMed ID: 36919067
[TBL] [Abstract][Full Text] [Related]
13. Controversies and Challenges in the Management of Osteosarcoma-an Indian Perspective.
Mittal A; Pushpam D; Ganguly S; Kumar VS; Khan SA; Bakhshi S
Indian J Surg Oncol; 2022 Dec; 13(4):939-955. PubMed ID: 36687236
[TBL] [Abstract][Full Text] [Related]
14. Determinants and impact of diagnostic interval in bone sarcomas: A retrospective cohort study.
Sasi A; Ganguly S; Biswas B; Pushpam D; Kumar A; Agarwala S; Khan SA; Kumar VS; Deo S; Sharma DN; Bakhshi S
Pediatr Blood Cancer; 2023 Mar; 70(3):e30135. PubMed ID: 36524611
[TBL] [Abstract][Full Text] [Related]
15. Sex disparity in childhood cancer in India: a multi-centre, individual patient data analysis.
Bhatia KP; Ganguly S; Sasi A; Kumar V; Deo S; Agarwala S; Radhakrishnan V; Swaminathan R; Kapoor G; Manoharan N; Malhotra S; Pushpam D; Bakhshi S
Lancet Oncol; 2023 Jan; 24(1):54-63. PubMed ID: 36455568
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
